Press

Evonik is extending its corporate-venturing activities in Europe with an investment in High-Tech Gründerfonds III (HTGF III). The fund has a targeted fund size of more than €300 million. Evonik will invest an amount in the single-digit million euro range. HTGF is Germany’s most active seed-stage investor. It finances young, innovative technology start-up companies and actively supports them with the implementation of their business ideas. In 2012, Evonik invested in the predecessor fund HTG

The STIHL Group is participating in the High-Tech Gründerfonds (Startup Fund), which is the largest seed fund for financing young technology companies in Germany. “By investing in the High-Tech Gründerfonds we want to support the development of innovative companies and further expand our activities in the area of research and development”, explained STIHL Executive Board Member, Finance and Controlling, Karl Angler. “The broad investment horizon of the High-Tech Gründerfonds and the

media + more venture Beteiligungs GmbH & Co. KG, a company comprising three regional publishers in Mainz, Freiburg and Heilbronn, is investing EUR 2.5 million in High-Tech Gründerfonds III (HTGF III). The consortium of three publishers is thus once again reinforcing its commitment to and investments in innovative technologies from Germany for the publishing industry. HTGF III invests venture capital in young, high potential high-tech start-ups that can turn promising research findings in

Complementing investments in venture capital funds as part of digital initiative Haniel, a German family-equity company, has invested in High-Tech Gründerfonds III (HTGF III). With HTGF III, up to 40 technology companies are expected to receive financial support with a target fund volume of €300 million per year. In addition to its financial involvement, the fund offers technology companies the expertise of its own team as well as an extensive network and scouts as support. Haniel benefits

Oldenburg-based chemicals company takes stake in High-Tech Gründerfonds “I am delighted that BÜFA GmbH & Co. KG has decided to invest in High-Tech Gründerfonds. With your support, we intend to continue the success enjoyed by High-Tech Gründerfonds, a development that benefits Germany as a hub of business,” German cabinet minister Sigmar Gabriel wrote in an official letter to BÜFA, thanking the company for its commitment. The Oldenburg-based chemicals company invested in the third

Telecommunication service provider Drillisch AG is investing in the third fund of High-Tech Gründerfonds (HTGF), Germany's most active seed stage investor. HTGF's third fund is to have a volume of roughly EUR 300 million. Drillisch AG joins an esteemed group of investors in the fund. The company owns a number of renowned brands including smartmobil.de, yourfone, simply, sim.de, McSIM, helloMobil, winSIM and discoTEL. "The investment in HTGF provides Drillisch AG and its subsidiary compani

Hogg Robinson Group announces that it has entered into an agreement to acquire the digital travel innovator eWings.com, a next-generation travel management company.  The acquisition is expected to complete within the next 15 working days. A totally online offering, eWings.com provides a fast and easy-to-use solution for digital business travel with a quick to start process and low cost service model which is especially well suited to small businesses that require a simplified digital Service.

Minimally invasive, highly conformable, foldable and stretchable electrodes for growing Neuromonitoring and Neuromodulation markets being developed WISE Srl, a medical device company developing next-generation implantable neuromodulation leads announces today the closing of a EUR 6.5 million series B financing round, led by Principia SGR, an Italian Venture Capital firm. Existing investors Atlante Ventures, High-Tech Gründerfonds, F3F and Antares joined the round. WISE develops novel, highly

High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection of possible side effects during the drug development process. Thereby, the need for animal testing will be reduced while the drug becomes safer and the process more cost-efficient. S

The Dusseldorf university spin-off NUMAFERM specializes in the biotechnical production of peptides and is able, through its newly developed platform technology, to dramatically reduce costs for this raw material. For the further technological development and an accelerated market entry, NUMAFERM GmbH is now receiving funding in the seven-digit range. High-Tech Gründerfonds (HTGF), Qiagen co-founders and European Business Angels Prof. Detlev Riesner and Dr. Jürgen Schumacher, as well as the Eur